Altimmune Inc (ALT)
6.79
+0.05
(+0.74%)
USD |
NASDAQ |
Nov 04, 16:00
6.76
-0.03
(-0.44%)
After-Hours: 20:00
Altimmune Research and Development Expense (Annual): 65.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 65.80M |
| December 31, 2022 | 70.54M |
| December 31, 2021 | 74.54M |
| December 31, 2020 | 49.77M |
| December 31, 2019 | 17.77M |
| December 31, 2018 | 18.46M |
| December 31, 2017 | 18.41M |
| December 31, 2016 | 7.222M |
| December 31, 2015 | 5.134M |
| Date | Value |
|---|---|
| December 31, 2014 | 9.320M |
| December 31, 2013 | 15.29M |
| December 31, 2012 | 19.51M |
| December 31, 2011 | 21.22M |
| December 31, 2010 | 20.88M |
| December 31, 2009 | 30.22M |
| December 31, 2008 | 31.81M |
| December 31, 2007 | 16.56M |
| December 31, 2006 | 7.259M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.77M
Minimum
2019
74.54M
Maximum
2021
55.68M
Average
65.80M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Eli Lilly and Co | 9.313B |
| Viking Therapeutics Inc | 63.81M |
| Amgen Inc | 4.784B |
| Avid Bioservices Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.068M |